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Purpose: A novel method for differentiating and treating bipolar disorder cycling on the depres-
sive pole from patients who are suffering a major depressive episode is explored in this work. 
To confirm the diagnosis of type 1 or type 2 bipolar disorder, the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV) criteria require that at least one manic or hypomanic 
episode be identified. History of one or more manic or hypomanic episodes may be impossible 
to obtain, representing a potential blind spot in the DSM-IV diagnostic criteria. Many bipolar 
patients who cycle primarily on the depressive side for many years carry a misdiagnosis of 
recurrent major depression, leading to treatment with antidepressants that achieve little or 
no relief of symptoms. This article discusses a novel approach for diagnosing and treating 
patients with bipolar disorder cycling on the depressive pole versus patients with recurrent 
major depression.
Patients and methods: Patients involved in this study were formally diagnosed with recurrent 
major depression under DSM-IV criteria and had no medical history of mania or hypomania to 
support the diagnosis of bipolar disorder. All patients had suffered multiple depression treatment 
failures in the past, when evaluated under DSM-IV guidelines, secondary to administration of 
antidepressant drugs and/or serotonin with dopamine amino acid precursors.
Results: This study contained 1600 patients who were diagnosed with recurrent major depres-
sion under the DSM-IV criteria. All patients had no medical history of mania or hypomania. All 
patients experienced no relief of depression symptoms on level 3 amino acid dosing values of 
the amino acid precursor dosing protocol. Of 1600 patients studied, 117 (7.3%) nonresponder 
patients were identified who experienced no relief of depression symptoms when the serotonin 
and dopamine amino acid precursor dosing values were adjusted to establish urinary serotonin 
and urinary dopamine levels in the Phase III therapeutic ranges. All of the 117 nonresponders 
who achieved no relief of depression symptoms were continued on this amino acid dosing 
value, and a mood-stabilizing drug was started. At this point, complete relief of depression 
symptoms, under evaluation with DSM-IV criteria, was noted in 114 patients within 1–5 days. 
With further dose adjustment of the mood-stabilizing drug, the remaining three nonresponders 
achieved relief of depression symptoms.
Conclusion: Resolution of depression symptoms with the addition of a mood-stabilizing drug 
in combination with proper levels of serotonin and dopamine amino acid precursors was the 
basis for a clinical diagnosis of bipolar disorder cycling on the depressive pole.
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Introduction
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  history must include one or more manic or hypomanic 
  episodes, respectively.1 The history of mania or hypomania 
may be obscure or nonexistent. For example, the bipolar 
patient may be cycling heavily on the depressive pole with 
the last manic or hypomanic episode having occurred many 
years ago. This episode may have lasted for only 2 weeks, 
during which time neither the patient nor others around the 
patient ever appreciated its presence. This obscured medical 
history represents a potential blind spot in the DSM-IV crite-
ria for diagnosing bipolar disorder cycling on the depressive 
pole. It is not uncommon in patients with bipolar disorder 
cycling on the depressive pole, while looking for relief of 
depression symptoms, to get caught in a seemingly endless 
cycle of shopping for health care providers. These physi-
cians may have prescribed most or all of the antidepressants 
medically available for treatment without getting complete 
relief of depression symptoms. This potential blind spot in 
the DSM-IV criteria leads to a misdiagnosis of recurrent 
major depression.
The novel approach described in this writing requires the 
administration of serotonin and dopamine amino acid precur-
sors with cofactors to reach the Phase III therapeutic ranges 
(herein referred to as the target ranges) as guided by the use 
of urinary serotonin and urinary dopamine organic cation 
transporter (OCT) functional status determination (herein 
referred to as ‘OCT assay interpretation’).2–5
The basis for the OCT assay interpretation model requires 
two or more serial urinary serotonin and dopamine assays 
while taking varied amino acid precursor daily dosing values. 
Results of two or more assays are then compared in order 
to determine the change in urinary serotonin and dopamine 
levels in response to the change in dosing. A urinary sero-
tonin or dopamine value ,80 or 475 µg of monoamine per 
gram of creatinine, respectively, indicates Phase II responses. 
A   urinary serotonin or dopamine value .80 or 475 µg of 
monoamine per gram of creatinine, respectively, is interpreted 
as being in Phase I or Phase III. Differentiation of Phase I 
from Phase III is a follows. If a direct correlation is found 
between amino acid dosing and urinary assay response, it 
is referred to as a Phase III response. An inverse correlation 
is referred to as a Phase I response. The Phase III   therapeutic 
range for urinary serotonin is defined as 80–240 µg of 
  serotonin per gram of creatinine. The Phase III therapeutic 
range for urinary dopamine is defined as 475–1100 µg of 
dopamine per gram of creatinine.2–5
Peer-reviewed scientific publications discussing urinary 
serotonin and urinary dopamine phase analysis under the 
OCT model were published in 20092,4 and 2010.3,5 These 
publications outlined the mechanisms of the ‘three-phase 
model’ in connection with urinary serotonin and urinary dop-
amine under a novel renal transporter model. This transporter 
model potentially describes the etiology of the ‘three-phase 
response’ in monoamine assays during the administration of 
varied amino acid precursor daily dosing values.3 Urinary 
serotonin and dopamine levels are primarily dependent upon 
the interaction of the basolateral monoamine transporters 
with the apical monoamine transporters of the proximal 
convoluted renal tubule cells of the kidneys.3
Most notable with this novel approach is the ability to 
differentiate patients with bipolar disorder cycling on the 
depressive pole from patients suffering from recurrent major 
depression, and then implement effective treatment.
Material and methods
Processing, management, and assay of the urine samples 
collected for this study were as follows. Urine samples were 
collected 6 h prior to bedtime with 4:00 PM being the most 
frequent collection time point. The samples were stabilized in 
6 N HCl to preserve urinary dopamine and urinary serotonin. 
The urine samples were collected after a minimum of 1 week 
during which the patient was taking a specific daily dosing 
of amino acid precursors of serotonin and dopamine where 
no doses were missed. Samples were shipped to DBS Labo-
ratories (Duluth, MN), which is operated under the direction 
of one of the authors (Thomas Uncini, MD, hospital-based 
pathologist, dual board certified in laboratory medicine and 
forensic pathology). Urinary dopamine and serotonin were 
assayed utilizing commercially available radioimmunoassay 
kits (3 CAT RIA IB88501 and IB89527; Immuno Biological 
Laboratories, Inc.,   Minneapolis, MN). The DBS laboratory 
is accredited as a high complexity laboratory by Clinical 
Laboratory Improvement Amendments to perform these 
assays.3,6
The protocol
The protocol for treatment of depression consisted of the 
amino acid dosing values found in Table 1. This protocol was 
covered in previous peer-reviewed literature.2
The initial step of the protocol was the administration 
of serotonin and dopamine amino acid precursors with no 
OCT assay interpretation. Three dosing levels were available 
as noted in Table 1. At the first visit, patients were started on 
level 1 amino acid dosing. Patients were then seen weekly 
for follow-up clinic visits.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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The question to be answered in evaluating patients after 
1 week of taking a specific amino acid dosing value was 
‘What was the status of the depression symptoms yesterday?’ 
Since it takes up to 5 days for the maximum benefit of an 
amino acid dosing change to be seen, secondary to equilibra-
tion of the amino acids, results from the day before the visit 
were found to be more reliable than inquiring about the status 
of depression symptom for the entire week.
Since the maximum benefit of any dosing change occurs 
within 5 days, there is no purpose in waiting longer than 1 week 
to see if an amino acid dosing change achieved additional relief 
of symptoms. This only increases the amount of time needed to 
find the proper dose leading to resolution of the symptoms.7
If there was no relief of depression symptoms at the 
weekly visit, the amino acid dosing was adjusted upward 
to the next dosing level (level 2 or level 3). The goal was 
to obtain relief of depression symptoms or reach level 3 
amino acid dosing with no relief of symptoms, whichever 
occurred first.2
At the initial visit, all prescription drugs were continued. 
Prescription antidepressant drugs were continued until full 
relief of depression symptoms was obtained, and then tapered 
to a stop, at the option of the caregiver. It was noted that 
drugs may require being stopped sooner if drug side effects 
emerge. As neurotransmitter levels increase with amino acid 
precursor administration, drug side effects may occur in ∼5% 
of patients. The emergence of drug side effects may be a 
source of confusion for the caregiver. Since the last thing 
changed in the patient’s treatment plan was the amino acid 
dosing, there is a tendency to focus on the amino acids as the 
source of side effects that were actually due to prescription 
drug toxic side effects.
Failure to achieve relief of depression symptoms, on 
evaluation with DSM-IV guidelines, after 1 week of taking 
level 3 amino acid dosing of Table 1 was the indication for 
initiation of OCT assay interpretation studies to guide further 
amino acid precursor dosing value changes.
Subsequent to the interpretation of each urine sample 
collected, the amino acid dosing was adjusted in response 
to OCT assay interpretation findings. This was focused on 
achieving both the urinary serotonin and dopamine in the 
Phase III therapeutic ranges (the target ranges). The end 
point of collecting samples for OCT assay interpretation 
was whichever came first of the following: i) resolution of 
depression symptoms, ii) obtaining both the urinary serotonin 
and dopamine in the target ranges, or iii) the patient dropping 
out of treatment.
If no relief of depression symptoms was observed with 
the urinary serotonin and dopamine in the target ranges, 
the amino acids were continued at that dosing value 
and a mood-stabilizing drug was added. The choice of 
mood-stabilizing drug was either lithium carbonate 300 mg 
twice a day or divalprex sodium 250 mg 3 times a day at the 
caregiver’s discretion.
l-Dopa and l-tyrosine have an ability to deplete sulfur 
amino acids. Based on previous experience and peer-
reviewed literature, l-cysteine was added to the serotonin 
and dopamine amino acid precursors in the amounts 
of 4500 mg/day in adults in divided doses.2 Selenium 
400 mcg/day was administered with the l-cysteine to address 
concerns raised in the literature regarding l-cysteine facili-
tating neurotoxic insult by methylmercury.8 Other literature 
notes that selenium irreversibly binds to methylmercury 
rendering it nontoxic.9
Results
Patients selected had been formally diagnosed with depres-
sion under DSM-IV criteria and carried no previous diagnosis 
or medical history supporting bipolar disorder.
The group studied consisted of 1600 patients diagnosed 
with recurrent major depression who failed to respond to 
treatment with amino acid precursors at the level 3   dosing 
(outlined in Table 1) on evaluation under DSM-IV   guidelines. 
These 1600 patients had urine samples collected, and OCT 
AM NOON 4 PM 7 PM
Level 1
Level 2
Level 3
150/1,500
150/1,500
150/1,500 150/1,500
150/1,500
150/1,500
300/1,000
300/1,000 300/1,000
-----
-----
-----
Milligrams 5-HTP/Milligrams L-Tyrosine
Table 1 Amino acid precursor dosing protocol. subjects also received the following daily dosing values of cofactors: 1) 1000 mg vitamin c, 2) 220 mg calcium citrate, 3) 75 
mg vitamin B6, and 4) 400 µg folate. copyright © 2009, crc Press. Adapted with permission from Hinz M. Depression. in: Kohlstadt i, editor. Food and Nutrients in Disease 
Management. Boca raton, FL: crc Press; 2009:465–481.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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assay interpretation was performed with amino acid dosing 
adjustments focused on achieving urinary serotonin and 
dopamine in the target ranges.
The status of depression symptoms was evaluated with 
the DSM-IV criteria at each visit. Of the 1600 patients 
starting the OCT assay interpretation, the following three 
groupings of patients ultimately were defined: i) patients 
who achieved relief of symptoms in response to amino 
acid   precursor   dosing value adjustment guided by OCT 
assay interpretation, ii) patients who achieved no relief of 
symptoms with the amino acid precursor dosing required 
for achieving urinary serotonin and dopamine in the target 
ranges, and iii) patients who dropped out of treatment.
Patients achieving relief of symptoms with amino acid 
dose adjustment and patients dropping out were not tracked 
in this study. The goal of the study was to define a group of 
patients who were nonresponders with urinary serotonin and 
dopamine in the target ranges. Of the initial starting group 
of N = 1600, a group of N = 117 (7.3%) was determined to 
be nonresponders.
Demographics of the 117 nonresponders were as fol-
lows. There were 73 females in the nonresponder group 
(62.4%). There were 44 males in the nonresponder group 
(37.6%). The age range for the entire nonresponder group was 
18.3–82.9 with a mean age of 55.2 and a standard deviation 
of 13.2 years. The age range for the female nonresponder 
group (N = 73) was 18.3–75.3 with a mean of 53.8 and a 
standard deviation of 11.9 years. The age range for the male 
nonresponder group (N = 44) was 25.0–82.9 with a mean of 
55.2 and a standard deviation of 13.2 years.
Nonresponders were continued on the amino acid 
dosing values needed to achieve the target ranges and a 
mood-stabilizing drug was started. The choice and dose of 
the mood-stabilizing drugs were lithium carbonate 300 mg 
twice a day or divalprex sodium 250 mg 3 times a day, at the 
caregiver’s discretion.
Of the 117 patients started on a mood-stabilizing drug 
in combination with the amino acid dosing needed to estab-
lish the target ranges, 114 achieved full relief of depression 
symptoms within 1–5 days of starting the drug. Of the 
three patients who did not respond when the initial dose of 
the mood-stabilizing drug was added, further adjustment 
of the mood-stabilizing drug was guided by serum assays 
of the drug levels with the goal of establishing lithium or 
  valproic acid serum levels in the therapeutic range. During the 
process of serum-guided adjustment of the mood-stabilizing 
drug, relief of depression symptoms was obtained in the 
final three patients. A positive response to adding the mood-
stabilizing drug to the amino acid dosing of the target ranges   
was the basis for a clinical diagnosis of bipolar disorder 
cycling on the depressive pole. The type was considered undif-
ferentiated since no history of mania or hypomania existed.
The conclusion was that 100% of patients in whom a 
mood-stabilizing drug was administered in conjunction with 
amino acid precursors were clinically diagnosed with bipolar 
disorder cycling on the depressive pole, while experiencing 
complete relief of depression symptoms. A significant point 
is the dramatic response of these patients to the starting 
dose of the mood-stabilizing drug. Up until initiation of the 
mood-stabilizing drug, none of the patients had experienced 
any relief or improvement of depression symptoms. The start-
ing dose of the mood-stabilizing drugs was well tolerated 
with no reported start-up problems.
The choice of which mood-stabilizing drug to prescribe 
was at the discretion of the caregiver; 71% of patients were 
treated with lithium carbonate, and 29% of patients were 
treated with divalprex sodium. Analysis of results revealed no 
significant difference in outcomes with the mood-stabilizing 
drug selected. Both mood-stabilizing drugs appear to 
be equally effective with all patients achieving relief of 
depression symptoms due to bipolar disorder cycling on the 
depressive pole.
Review of group amino acid dosing values, where both 
the urinary serotonin and dopamine were in the target ranges, 
revealed daily dosing values were highly individualized with 
no standard dosing apparent. In the group of 117 nonre-
sponders to amino acids alone, the group amino acid dosing 
values in the target ranges were as follows.
The group 5-HTP dosing range was 37.5–1800 mg/day 
with a mean of 300 mg/day and a standard deviation 
of 380.5 mg/day. l-Tyrosine group dosing range was 
2500–13,000 mg/day with a mean of 7000 mg/day and a 
standard deviation of 2148.5 mg/day. l-Dopa group dosing 
range was 0–2940 mg/day with a mean of 240 mg/day and 
a standard deviation of 285.8 mg/day.6
Treatment time to stabilization was as follows. All patients 
at the start of the study had undergone 3 weeks of treatment 
utilizing the amino acid dosing value adjustment under the 
protocol of Table 1. Time to achieve urinary serotonin and 
dopamine in the Phase III therapeutic ranges beyond level 3 
dosing was 2–12 weeks with a mean of 6 weeks and a stan-
dard deviation of 2.23 weeks. In 114 of the patients started 
on a mood-stabilizing drug, one additional week of treatment 
time was required to achieve relief of symptoms. The average Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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time of treatment from start of the amino acids in Table 1 to 
relief of symptoms with the mood-stabilizing drugs was 10 
weeks with a range of 6–16 weeks.
Physicians involved in this study reported no relapse of 
depression symptoms as long as patients were compliant 
with treatment prescribed. The longest follow-up period for 
a patient in this study is currently 8 years.
Discussion
The clinical diagnosis of depression was made in the pri-
mary care setting. It was indicated that the diagnosis of 
depression had been made under DSM-IV criteria. There 
were no reports of structure interviews being performed 
in these practices which may represent a limitation of this 
depression care.
While the approach of administering l-tyrosine with 
l-dopa may seem counterintuitive, the rationale for its use 
is supported by the literature and the research experience 
leading up to this article. Peer-reviewed literature notes 
administering l-dopa without proper levels of l-tyrosine can 
lead to significant fluctuations in urinary dopamine levels. 
Dopamine fluctuations interfere with OCT assay interpreta-
tion, leading to inconsistent results. Dopamine fluctuations 
can also decrease the efficacy of l-dopa, as the clinical 
response fluctuates.4 It is also known that administration of 
l-dopa can lead to depletion of l-tyrosine.10
The effects of mood-stabilizing drugs (lithium carbonate 
or divalprex sodium) used in this study appear to be potenti-
ated by the serotonin and dopamine amino acid precursor in 
dosing values needed to establish the target ranges. There 
appears to be a synergy. The mechanism of this potential 
synergy is unknown. In this pilot study, patients who were 
diagnosed with bipolar disorder cycling on the depressive 
pole experienced no relief of symptoms in the past although 
mood-stabilizing drugs were administered at various dos-
ing values including levels verified as therapeutic by serum 
assays. In this study, they obtained relief of symptoms 
predominantly on the starting dose of drug when added to 
amino acid precursors at dosing values required to establish 
the target ranges.
The following patient profile exists for those patients 
newly diagnosed in this study with bipolar disorder 
cycling on the depressive pole under this protocol. The 
typical patient has a history of being treated with antide-
pressants for recurrent major depression for many years 
without relief of depression symptoms. Once symptoms 
of depression are under control, with the addition of a 
mood-stabilizing drug, it is not uncommon for patients to 
report that their symptoms have been present since high 
school or earlier in life. Patient reports of suffering since 
high school are common and even more impressive when 
it is realized that 80% of the patients in this study ranged 
from 40 to 65 years of age, meaning years of suffering 
without effective treatment.
Over the years, these patients have seen many physicians 
while looking for relief of depression symptoms and 
have taken most or all of the antidepressants available 
without complete relief of symptoms.2 It is suggested 
that future studies of this protocol which differentiates 
bipolar depression from recurrent major depression should 
incorporate the following screening in order to generate a 
group with a higher percentage of previously undiagnosed 
bipolar disorder cycling on the depressive pole. i) A history 
of depression for over 10 years. ii) A history of having 
seen five or more caregivers for treatment of depression. 
iii) A history of   having taken five or more antidepressant 
drugs in the past without full relief of symptoms. It is also 
suggested that in patients who meet this criteria, the amino 
acid dosing simply be started on level 1 dosing of Table 1 
and then a urine sample be obtained in 1 week and submitted 
for OCT assay interpretation. This will decrease the time of 
treatment by 3 weeks.
As noted previously, when this protocol was initiated, 
any prescription drugs being taken were continued. Once the 
patient with bipolar disorder cycling on the depressive pole 
achieves relief of depression symptoms and the diagnosis of 
bipolar disorder cycling on the depressive pole is made, any 
antidepressants, which are not indicated for monotherapy for 
treatment with bipolar depression under US Food and Drug 
Administration (FDA) guidelines, should be stopped.6,7,11,12 
However, it was found that many of these patients, finally 
symptom free for the first time in years, are hesitant or even 
highly resistant to giving up anything in their treatment plan 
that has finally gotten them relief of symptoms, including the 
antidepressants. These   feelings on the part of the patient may 
be exceptionally strong. An effective approach to eliminating 
the antidepressants that are not indicated for monotherapy 
in bipolar depression from the treatment plan, in the face 
of strong patient resistance, is to simply wait 2–3 months 
after relief of symptoms and then revisit the issue of slowly 
tapering the antidepressants to a stop.
Implementation of this protocol is time intensive. 
The amino acid dosing value OCT assay interpretation 
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changed, it takes 1 week before urine can be collected in 
the steady state, and then it takes another week to get the 
test results of OCT assay interpretation reported back to the 
  physician in order to prescribe the next amino acid dosing 
value. Patients at initial visit orientation and on follow-up 
visits need to be prepared for the longest treatment time 
possible (2–4 months), although some patients may find 
relief of symptoms in 1–2 weeks. This is done to prevent 
patients from dropping out of treatment due to perceived 
lack of results after several weeks. Response time under 
this approach varies greatly. Since there is no way of 
predicting at which point in this process the patient will 
achieve relief of symptoms, all patients need to be properly 
oriented at the first visit to the indeterminate length of time 
with reinforcement of this orientation at subsequent visits. 
While weekly visits over a 4-month period may seem like 
a long time to get relief of symptoms, in fact, most bipolar 
disorder cycling on the depressive pole have suffered with 
disease symptoms for 20–40 years or longer and the time 
investment is relatively small compared to the prolonged 
length of suffering and the cost due to ineffectiveness of 
previous medical care.
As treatment under this protocol progresses, most patients 
report no relief of depression symptoms until the proper 
amino acid dosing or amino acid dosing with mood-stabilizer 
dosing has been implemented. It was relatively rare for 
patients to achieve gradual relief of symptoms from visit to 
visit. Resolution of symptoms in patients can be and often is 
dramatic and abrupt, analogous to a light switch being either 
off (with symptoms) or on (without symptoms). It was not 
uncommon for a patient who had been under treatment for 
many weeks to return for a clinic visit and report the exact 
day that relief of depression symptoms occurred. Waiting for 
this dramatic effect to occur without the patient understand-
ing the process involved may lead to an increased drop-out 
rate of patients prior to relief of symptoms. For example, the 
patient who has been under treatment for many weeks, with 
no improvement of depression, may contemplate dropping 
out of treatment when, in fact, they are on the doorstep of 
dramatic improvement.
Conclusion
The novel approach of this pilot study clinically differenti-
ates recurrent major depression from bipolar disorder cycling 
on the depressive pole. Although this approach appears to 
be effective in treatment of bipolar disorder cycling on the 
depressive pole, more studies are needed.
Bipolar disorder cycling on the depressive pole is fre-
quently misdiagnosed by caregivers. One of the primary 
stumbling blocks is the inability to elicit a proper medical 
history of one or more manic or hypomanic episodes in 
the patient’s past in order to satisfy the DSM-IV criteria. 
This potential blind spot in the DSM-IV criteria leads to 
antidepressants being prescribed to patients with bipolar 
depression, a practice that is specifically not indicated as 
monotherapy under FDA guidelines.6,7,11,12
The protocol of this study has been in use since 2004 
with no reported failures in the treatment of bipolar disor-
der cycling on the depressive pole when the protocol was 
followed properly. This is a pilot study. The intent of this 
article is to disseminate some of the knowledge gained in 
this research, spark interest leading to more research, refine 
the protocol with more studies, and elicit scrutiny of these 
observations.
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